NVS Today - Aug 13: Small Dip After FDA News

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

NVS Today - Aug 13: Small Dip After FDA News

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly neighborhood investor. I’ve been in the game for a while, and today I’m breaking down Novartis, ticker NVS. So, how did it do? Well, it had a bit of a rough day, ending down just a smidge—like, barely moving, just a 0.04% dip.

So, what went down? Well, the stock kinda got smoked after some news hit about Pluvicto, which is one of their cancer treatments. The FDA gave a thumbs up for a combo approval, but it looks like traders weren’t too thrilled, and they hit that sell button fast. It’s like when your favorite band releases a new song, and it’s just not what you expected.

Now, let’s talk about why all this happened. First off, Novartis did win a court challenge in the UK related to its Entresto patent, which is a win for them, but the market seemed to shrug it off. Maybe folks were more focused on that Pluvicto news. Plus, I saw some reports saying that some big investors, like Triasima and Mission Wealth Management, are making moves with their shares—some buying more, others trimming down. It’s like a game of musical chairs where no one wants to be left standing when the music stops.

And speaking of the horizon, Novartis is working on optimizing its supply chain, which could be a big deal moving forward. If they nail that, it might help them streamline operations and improve profits.

So, yeah, today was a bit of a bummer for Novartis, but there’s always something brewing in the background. Just remember, I’m here to keep you in the loop, but this isn’t financial advice. Just some friendly chatter about the stock world. Catch you later!

まだレビューはありません